X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 11, 2023
Details:
KX-826 (pyrilutamide) is a monoclonal antibody drug candidate with potential AR antagonistic action, is being developed as a potential topical drug for the treatment of androgenic alopecia and acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2023
Details:
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2022
Details:
KX-826 (pyrilutamide) is an AR antagonist and a potential first-in-class topical drug for treatment of androgenetic alopecia and acne vulgaris continues to demonstrate good efficacy and safety in phase II clinical trial to benefit more people suffering from acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2022
Details:
KX-826 (pruxelutamide) effectively reduced hospitalization/mortality; in particular, for subjects who completed the medication for more than 7 days and middle-and-high-age COVID-19 patients with high risk factors, the protection rate was 100%.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: IQVIA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
Kintor Pharma announced that the primary endpoint of the phase II clinical trial of KX-826 (pyrilutamide) on adult male patients was met, with results demonstrating a positive safety profile and good efficacy.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
KX-826 is an androgen receptor antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. The primary endpoint of the phase II clinical trial of KX-826 on adult male patients was met, as results showed good efficacy and safety profile.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 06, 2022
Details:
KX-826 is an androgen receptor (AR) antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. KX-826 has showed good efficacy and safety profile in the phase II clinical trial in China for the treatment of AGA male patients.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
KX-826 (pyrilutamide) is first androgen receptor antagonist which has entered phase III clinical trial for male androgenetic alopecia treatment in China and global. Primary endpoint of KX-826 on male AGA patients met and demonstrated outstanding efficacy and safety profile.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021
Details:
The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Pyrilutamide in patients with mild to moderate acne vulgaris.
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
